3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
13
Prostatic Neoplasms
9
Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Cardiovascular Diseases
3
Cardiotoxicity
3
Triple Negative Breast Neoplasms
2
Polycystic Ovary Syndrome
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Kidney Neoplasms
2
Heart Failure
2
Endometrial Hyperplasia
2
Carcinoma, Renal Cell
2
Waldenstrom Macroglobulinemia
1
Venous Thrombosis
1
Urogenital Neoplasms
1
Smoking
1
Sarcoma
1
Rectal Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Overall Survival
1
Ototoxicity
1
Interventions
Surveys and Questionnaires
6
Standard of Care
6
Blood Specimen Collection
6
BNT162 Vaccine
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Specimen Handling
3
Practice Guidelines as Topic
3
COVID-19 Vaccines
3
2019-nCoV Vaccine mRNA-1273
3
tocilizumab
2
sotrovimab
2
Pandemic Preparedness
2
CVnCoV COVID-19 vaccine
2
Azithromycin
2
sinovac COVID-19 vaccine
1
selinexor
1
remdesivir
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
cilgavimab and tixagevimab drug combination
1
ciclesonide
1
avdoralimab
1
XAV-19
1
Therapeutics
1
Telemedicine
1
Sperm Count
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
COVID-19
×
Atorvastatin
×
Clear all
NCT04904536
2025-04-10
STRONGER
The George Institute
Phase 3
Active not recruiting
190 enrolled